Predictive Technology Group Inc (PRED)

[Brian903]

TA Yap has received research funding from AstraZeneca, Vertex Pharmaceuticals and Clearbridge Biomedics. He is also an advisory board member for AstraZeneca, Pfizer Inc, EMD Serono, Clovis, Bristol-Myers Squibb, Ignyta, Roche, Janssen Pharmaceuticals, Atrin and Aduro and has received travel support from AstraZeneca, Bristol-Myers Squibb, Merck Sharp Dohme, Vertex Pharmaceuticals, GlaxoSmithKline, EMD Serono and Tesaro.

Link to a Yap
https://faculty.mdanderson.org/profiles/timothy_yap.html

Dr. Yap’s main research focuses on the first-in-human and combinatorial development of molecularly targeted agents and immunotherapies, and their acceleration through clinical studies using novel predictive and pharmacodynamic biomarkers. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, such as ATR and PARP inhibitors, as well as the development of novel immunotherapeutics. His laboratory interests included the development of patient-derived xenografts (PDXs) and circulating plasma DNA as predictive biomarkers of response for novel targeted agents and immunotherapies in clinical trials.